Eli Lilly (Italy)

Recent papers from Eli Lilly (Italy)

1. Abemaciclib plus endocrine therapy in high-risk, node-positive early breast cancer in Italian practice: interim analysis of prospective observational IT-PATH studyESMO Real World Data and Digital Oncology · 2026
2. Diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: Findings from an Italian real-world surveyJournal of Alzheimer s Disease · 2026
3. Canine Leishmaniosis in Italy: Geospatial Trends and Incidence, a Shift in Epidemiological ApproachZoonoses and Public Health · 2026
4. Interchangeability of CSF and PET to identify Alzheimer's disease pathologyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026
5. Justice beyond the StateContention · 2025
6. Abstract PS5-04-08: Abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: insights from an Italian retrospective observational studyClinical Cancer Research · 2026
7. A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.Journal of Clinical Oncology · 2026
8. Redefining management of mild cognitive impairment and Alzheimer's disease through the shift from clinical to clinical-biological diagnosis: Insights from a single-center experienceJournal of Alzheimer s Disease · 2026
9. Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and ColombiaDermatology and Therapy · 2025
10. Concordance Between Amyloid-PET Quantification and Real-World Visual ReadsJAMA Neurology · 2025
11. Development and Validation of a¹⁸F-Flortaucipir PET Visual Stratification MethodJournal of Nuclear Medicine · 2025
12. Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in ItalyJournal of Diabetes & Metabolic Disorders · 2025
13. A practical overview of the use of amyloid-PET Centiloid values in clinical trials and researchNeuroImage Clinical · 2025
14. Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerCancer Research · 2024
15. Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United StatesBMC Cancer · 2024
16. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyJournal of Medical Economics · 2024
17. Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational StudyPain and Therapy · 2024
18. Real world evidence: patients with alopecia areata in ItalyItalian Journal of Dermatology and Venereology · 2024
19. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic CancerCancers · 2024
20. Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)Neurology and Therapy · 2024